CSIMarket Company Name, Ticker, Customers, else..
 
Immunocore Holdings Plc  (NASDAQ: IMCR)
 
Price: $34.5100 $-0.85 -2.404%
Day's High: $35.345001220703125 Week Perf: -7.65 %
Day's Low: $ 34.45 30 Day Perf: 1.56 %
Volume (M): 36,833 52 Wk High: $ 40.72
Volume (M$): $ 0 52 Wk Avg: $33.00
Open: $35.16 52 Wk Low: $27.56



 Market Capitalization (Millions $) 1,759
 Shares Outstanding (Millions) 51
 Employees 524
 Revenues (TTM) (Millions $) 431
 Net Income (TTM) (Millions $) -18
 Cash Flow (TTM) (Millions $) -35
 Capital Exp. (TTM) (Millions $) 10

Business Description


The company is a commercial-stage biotechnology firm developing immunomodulating medicines using its proprietary ImmTAX platform, which engineers soluble, bispecific T cell receptor (TCR) therapeutics targeting cancer, infectious diseases, and autoimmune diseases. Its lead product, KIMMTRAK, is approved in 39 countries for treating unresectable or metastatic uveal melanoma and is undergoing multiple Phase 3 clinical trials for melanoma. The company’s pipeline includes additional ImmTAC candidates in clinical trials for various cancers and infectious diseases, with ongoing expansion into autoimmune disease therapies.


   Company Address: 92 Park Drive Abingdon, Oxfordshire, 0
   Company Phone Number: 438600   Stock Exchange / Ticker: NASDAQ IMCR


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
ATRA        12.86% 
BEAM   -9.7%    
DNA   -1.15%    
IOVA        4.35% 
NVAX   -1.53%    
RGNX   -6.76%    
• View Complete Report
   



Clinical Study

“Emerging Innovations in Hepatitis B Treatment Immunocores Promising Phase 1 Data on IMC-I109V”

Published Fri, Nov 7 2025 1:47 PM UTC

Immunocore Presents Phase 1 Data for Hepatitis B Candidate at AASLD s The Liver Meeting In an era marked by remarkable advances in therapeutic strategies, Immunocore has taken a significant step forward in the battle against hepatitis B. At the prestigious American Association for the Study of Liver Diseases (AASLD) The Liver Meeting, held recently, the biopharmaceutical com...
Clinical Study

First Patient Enrolled in Landmark Phase 3 Trial for Uveal Melanoma, Paving the Way for Immunotherapy Advanceme...

Published Mon, Dec 30 2024 2:24 AM UTC

Uveal melanoma (UM) is the most common primary intraocular malignancy, characterized by its aggressive nature and propensity for metastasis. Annually, approximately 1,500 to 2,500 new cases are diagnosed in the United States alone. Despite advances in local therapies, a significant number of patients will develop metastatic disease, warranting the need for effective adjuvant...
Clinical Study

Navigating New Frontiers Immunocores Strategic Advances and Market Dynamics Amidst Intensifying Competition

Published Sun, Dec 29 2024 2:59 PM UTC

In the fast-paced world of biopharmaceutical innovation, Immunocore Holdings Plc continues to forge ahead with promising research endeavors, despite facing formidable competition on multiple fronts. A notable development for the company involves the recent announcement of initiating the Phase 1/2 trial of IMC-R117C a novel therapeutic candidate targeting the PIWIL1 protein ...
Announcement

Immunocore Secures Reimbursement for KIMMTRAK in England, Marking a Milestone in Uveal Melanoma Treatment

Published Tue, Dec 3 2024 6:00 AM UTC

Immunocore Holdings Plc (NASDAQ: IMCR) has announced a significant milestone in cancer treatment as it has finalized a reimbursement agreement in England for its innovative therapy, KIMMTRAK, aimed at HLA-A 02:01-positive adults suffering from unresectable or metastatic uveal melanoma. This landmark decision is expected to enhance patient access to a vital therapy that has s...
Clinical Study

Immunocore Advances Cancer Therapy Phase 1 Data on Brenetafusp Shows Promise in Ovarian Cancer Treatment

Published Sat, Sep 14 2024 7:00 AM UTC

Immunocore Holdings Plc has marked a significant milestone in the realm of cancer therapies, as the company recently presented encouraging Phase 1 data on brenetafusp, a novel ImmTAC (Immune Mobilizing Monoclonal T cell receptors Against Cancer) bispecific targeting the cancer/testis antigen PRAME (Preferentially Expressed Antigen in Melanoma). This development comes at a cr...



Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) -
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) 4.08
Price to Sales (Expected) -
Price to Book 4.19
PEG (TTM) -

Financial Strength Current
Quick Ratio 3.74
Working Capital Ratio 4.47
Leverage Ratio (MRQ) 1.67
Total Debt to Equity 0.94
Interest Coverage (TTM) -
Debt Coverage (TTM) 0

Per Share Current
Earnings (TTM) -0.38 $
Revenues (TTM) 8.45 $
Cash Flow (TTM) -
Cash 17.27 $
Book Value 8.24 $
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) 822,090
Net Income per Employee (TTM) -34,492
Receivable Turnover Ratio (TTM) -
Inventory Turnover Ratio (TTM) 0.67
Asset Turnover Ratio (TTM) 0.39

Profitability Ratios Current
Gross Margin (MRQ) 99.06 %
Operating Margin (MRQ) -2.58 %
Net Margin (MRQ) -0.7 %
Net Cash Flow Margin (MRQ) 0 %
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) -
Return On Investment (TTM) -
Return On Equity (TTM) -
Dividend Yield -
Pay out Ratio (TTM) -



Immunocore Holdings Plc's Segments
Sale of Therapies    18.2 % of total Revenue
Reportable    192.02 % of total Revenue





Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.